Summary The 2015 Magnetic Resonance Imaging in Multiple Sclerosis and 2016
Consortium of Multiple Sclerosis Centres guidelines on the use of MRI in diagnosis and …

The modern era of multiple sclerosis (MS) treatment began 25 years ago, with the approval
of IFNβ and glatiramer acetate for the treatment of relapsing–remitting MS. Ten years later …

Importance Within 2 decades of onset, 80% of untreated patients with relapsing-remitting
multiple sclerosis (MS) convert to a phase of irreversible disability accrual termed secondary …

Deep learning networks have recently been shown to outperform other segmentation
methods on various public, medical-image challenge datasets, particularly on metrics …

In the past 20 years the treatment scenario of multiple sclerosis has radically changed. The
increasing availability of effective disease-modifying therapies has shifted the aim of …

Multiple sclerosis (MS) is a chronic autoimmune, inflammatory neurological disease of the
central nervous system (CNS). 1, 2 MS attacks the myelinated axons in the CNS, destroying …

Background and purpose There is still no curative treatment for multiple sclerosis (MS), but
during the last 20 years eight different disease‐modifying compounds have been approved …

The discovery of fingolimod (FTY720/Gilenya; Novartis), an orally active immunomodulatory
drug, has opened up new approaches to the treatment of multiple sclerosis, the most …

Multiple sclerosis (MS) is an inflammatory-mediated demyelinating disease of the human
central nervous system. The clinical disease course is variable, usually starts with reversible …

Multiple sclerosis (MS) is a chronic inflammatory condition of the central nervous system
determined by a presumed autoimmune process mainly directed against myelin …